Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

NCT05295875 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT05295875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05295875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)
Lead sponsor
Altimmune, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2022
Completion date
September 28, 2023
Enrollment
391 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

obesity/overweight